Abstract
This chapter focuses on revascularization and reperfusion therapy in the setting of ACS. Revascularization therapy is distinct from reperfusion therapy. The former takes place in non-ST-elevation or ST-elevation ACS, while reperfusion is employed only for ST-elevation myocardial infarction. Revascularization therapy for non-ST-elevation ACS is usually considered an urgent condition unless there are signs of hemodynamic or electrical instability, in which case it is performed immediately. Instability in these patients may indicate a large burden of jeopardized myocardium or rather a disguised ST-elevation myocardial infarction, which, for example, can be seen with a circumflex artery occlusion. In contrast, reperfusion therapy is an emergent condition since it characterizes a state of coronary occlusion. A small subset of non-ST-elevation myocardial infarction patients will only receive medical therapy, even after coronary angiography. Revascularization is usually accomplished percutaneously, although some of these patients will be referred for surgical revascularization. While thrombolytic therapy is contraindicated for non-ST-elevation myocardial infarction, it has an important role in ST-elevation myocardial infarction when primary angioplasty is not readily available. Our discussion will begin with revascularization therapy and then move into reperfusion therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338:1785–1792.
Cannon CP, Weintraub WS, Demopoulos LA, et al.; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) — Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879–1887.
de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353:1095–1104.
Bavry AA, Kumbhani DJ, Quiroz R, et al. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST segment elevation acute coronary syndromes: a metaanalysis and review of the literature. Am J Cardiol 2004; 93:830–835.
Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1997; 30:141–148.
Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J 2004; 25:1641–1650.
Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48:1319–1325.
Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293:2908–2917.
Bhatt DL. To cath or not to cath: that is no longer the question. JAMA 2005; 293:2935–2937.
Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes. Results from the CRUSADE quality improvement initiative. JAMA 2004; 292:2096–2104.
Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction—Executive Summary. J Am Coll Cardiol 2007; 50:652–726.
Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007; 28:1598–1660.
Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45–54.
Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2005; 96:750–755.
Pasceri V, Patti G, Speciale G, et al. Meta-analysis of clinical trials on use of drug eluting stents for treatment of acute myocardial infarction. Am Heart J 2007; 153:749–754.
Bavry AA, Bhatt DL. Acute myocardial infarction and drug-eluting stents: a green light for their use or time for measured restraint? Am Heart J 2007; 153:719–721.
Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113:2803–2809.
Bavry AA, Bhatt DL. Drug-eluting stents: dual antiplatelet therapy for every survivor? Circulation 2007; 116:696–699.
Fibrinolytic Therapy Trialists’ Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarctin: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994; 343:311–322.
The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615–1622.
Keeley EC, Grines CL. Primary coronary intervention for acute myocardial infarction. JAMA 2004; 291:736–739.
Keeley EC, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13–20.
Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomized trials. Lancet 2006; 367:579–588.
Patel TN, Bavry AA, Kumbhani DJ, et al. A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis. Am J Cardiol 2006; 97:1685–1690.
Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353:2758–2768.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Current Medicine Group, a part of Springer Science+Business Media
About this chapter
Cite this chapter
Bavry, A.A., Bhatt, D.L. (2008). Revascularization and reperfusion therapy. In: Managing Acute Coronary Syndromes in Clinical Practice. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-14-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-908517-14-2_8
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-85873-413-2
Online ISBN: 978-1-908517-14-2
eBook Packages: Humanities, Social Sciences and LawHistory (R0)